Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Seattle Genetics Inc (NASDAQ:SGEN)

61.74
Delayed Data
As of Jun 23
 -1.51 / -2.39%
Today’s Change
35.93
Today|||52-Week Range
75.36
+17.00%
Year-to-Date
Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug
Jun 21 / Zacks.com - Paid Partner Content
Bristol-Myers Opdivo Positive in Phase II Study CheckMate-205
Jun 19 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt
Jun 21 / Zacks.com - Paid Partner Content
Biotech Movers: Clovis, Seattle Genetics, Rigel
Jun 19 / TheStreet.com - Paid Partner Content
Seattle Genetics Halts Phase III Study on Leukemia Drug
Jun 20 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close63.25
Today’s open62.95
Day’s range61.29 - 63.32
Volume1,460,389
Average volume (3 months)772,562
Market cap$8.8B
Dividend yield--
Data as of 3:59pm ET, 06/23/2017

Growth & Valuation

Earnings growth (last year)-7.53%
Earnings growth (this year)-67.64%
Earnings growth (next 5 years)-28.70%
Revenue growth (last year)+24.15%
P/E ratioNM
Price/Sales17.76
Price/Book13.85

Competitors

 Today’s
change
Today’s
% change
ALKSAlkermes Plc-0.21-0.36%
JAZZJazz Pharmaceuticals...-0.68-0.43%
TSROTESARO Inc-3.05-2.04%
ALNYAlnylam Pharmaceutic...+1.25+1.49%
Data as of 4:14pm ET, 06/23/2017

Financials

Next reporting dateAugust 3, 2017
EPS forecast (this quarter)-$0.42
Annual revenue (last year)$418.1M
Annual profit (last year)-$140.1M
Net profit margin-33.51%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Clay B. Siegall
Chief Operating Officer
Eric L. Dobmeier
Corporate headquarters
Bothell, Washington

Forecasts